Skip to content

Released Aug 9, 2017, after the close

10-Q filed Aug 9, 2017, 40 days after period end · 0001144204-17-041693

Q2 2017 · 10-Q
Revenue$6.36M+259.4% vs Q2 2016+120.1% vs Q1 2017
Net Income$450.00KN/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.06N/M vs Q2 2016N/M vs Q1 2017
Gross Profit$835,000+788.3%
Operating Income-$10,805,000N/M
Operating Cash Flowderived-$8,619,000N/M
Free Cash Flowderived-$8,942,000N/M
Margins · derived
Gross margin13.1%+7.8 pt vs Q2 2016
Operating margin-169.9%+391.4 pt vs Q2 2016
Net margin7.1%+620.6 pt vs Q2 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2017Q2 2016Q2 2015Q2 2014
Revenue$6.36M$1.77M$1.34M$2.43M
Net Income$450.00K-$10.85M-$5.07M-$6.12M
EPS Diluted-$0.06-$0.11-$0.05-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR